



Takeda—On the Move in the U.S.A.

Presented February 7, 2017



Our Priorities Built on Our Values – Takeda-ism





Our Footprint is Global





Our Coast-to-Coast Presence




Takeda has a strong commitment to the U.S. with more than 5,000 employees across multiple business units. Have full value chain capabilities: manufacturing, research, development and commercialization.



We are focusing our efforts in the therapeutic areas where we want to be at the cutting edge of innovation






1 Ongoing discovery platform to support autoimmune diseases, GI inflammation and CNS inflammation interests 2 Genitourinary, pain, others (e.g., sepsis)

Takeda Pharmaceutical Company Limited

Breakthroughs in science and medicine have led to increasing demand for innovation






Takeda will address this demand with a patient-centric, science-based strategy for world class R&D

We are building a network through innovative models to become among the best partners in the industry





STRATEGIC INTENT-5 years

We deliver customer-centric solutions that combine innovative medicines with valuable data, education and support to improve the lives of patients.

STRATEGIC IMPERATIVE – 2 years

Partner for Access	Invest to Win in Specialty	Drive Commercial Innovation
Create tailored partnerships with key stakeholders to improve patients' ability to get our medicines. Focus on insurers, Integrated Delivery Networks and Pharmacy Benefit Managers in the U.S.	Develop best in class capabilities in key account management, access and reimbursement, patient support, provider education and evidence generation.	Use multi-channel promotion within the work/life flow of our customers to maintain strong volume growth. Focus on consumer activation, patient adherence and provider confidence in disease and product.

Ensuring Access to Innovation



• Address barriers to paying for value

- Retain Medicare Part D protected class provision for most vulnerable patients
- Support efforts to limit step therapy requirements without clinical merit

• Preserve patient protections through ACA repeal/replace

• Takeda's Help at Hand

Better Health, Brighter Future





Presented February 7, 2017

Takeda Pharmaceutical Company Limited